SHENZHEN, China, July 16 /PRNewswire-Asia/ -- Mindray Medical International Limited (NYSE: MR, the Company), a leading developer, manufacturer and marketer of medical devices worldwide, today announced updates on new product launches and GPO relationships for the first half of 2009.
In the first half of 2009, the Company released a total of five products, including four new products in their patient monitoring and life support line and an upgrade to one of their medical imaging products. A full description of the products is provided below.
Mindray also announced today that Mindray USA, which sells the Datascope brand of patient monitors as well as a newly introduced DPM brand of patient monitors re-engineered for the North American market, has expanded its GPO contact base.
"We are very pleased with the progress we have made with our product development and GPO relationships," commented Mr. Xu Hang, Mindray's chairman and co-chief executive officer. "Earlier in the year we announced that we plan to launch seven to nine new products in 2009 and we are well on target for achieving that goal. Additionally, the DPM product line has now been added to contracts in five of the largest GPO's. This provides contracted access to this product line for over 85% of the U.S. hospitals and surgery centers. We will continue to seek to expand our distribution platforms and rapidly bring new high-quality and low-cost products to market while generating new revenue streams in an increasingly price-competitive medical device market."
Products
Patient Monitoring and Life Support
-- HyLite 6700/6500 -- is a surgical light that can provide sufficient
lighting for operations with excellent cavity-lighting capability.
-- HyBase 6100 -- is a surgical bed that offers a full-safety guarantee,
can suit various surgical disciplines, and provides maximum comfort and
great convenience to end users.
Both the HyLite 6700/6500 and HyBase 6100 received SFDA and CE marks and are brand new additions to the patient monitoring and life support line, providing even more comprehensive operating room solutions for end users.
-- Accutorr V vital signs monitor -- has received FDA approval and is the
company's first product jointly developed by Mindray's Mahwah U.S. and
Shenzhen China teams. It has the ability to track vital signs by
patient ID, a pulse waveform and a pulse strength indicator. The
Accutorr V offers fast, direct operations with comfort and ease and
comes standard with a LCD display, recorder and 1200 trend memory.
-- NetGuard Clinical Alert System -- has also received FDA approval and is
an innovative product developed by Mindray's Mahwah U.S. team; it can
monitor the electrical activity of patients' hearts and send automatic
alerts to clinical staff in the event of life-threatening cardiac
rhythms. This ground-breaking type of wireless cardiac monitoring can
potentially improve patient outcomes in the Emergency Department or any
area of the hospital in which it is utilized.
Medical Imaging
-- DP-6900 -- is an upgraded premium portable black and white ultrasound
system, which received CE mark, and, via advanced imaging technologies,
brings diagnostic confidence in a variety of clinical applications.
Together with huge image storage capacity, powerful workflow and
comprehensive software packages, it offers end users excellent image
quality and flexibility.
To further expand its product portfolio, Mindray expects to launch a total of seven to nine new products in 2009.
About Mindray
We are a leading developer, manufacturer and marketer of medical devices worldwide. We maintain global headquarters in Shenzhen, China, U.S. headquarters in Mahwah, New Jersey and multiple sales offices in major international markets. From our main manufacturing and engineering base in China and through our worldwide distribution network, we are able to supply internationally a broad range of products across three primary business segments, comprised of patient monitoring and life support products, in-vitro diagnostic products and medical imaging systems. For more information, please visit http://www.mindray.com .
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including those related to the development, shipment, and launch of new products, and the application for and receipt of FDA, CE mark, and SFDA regulatory clearance for our products. Statements that are not historical facts, including statements about new product releases and regulatory approvals are forward- looking statements. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors. Forward-looking statements involve inherent risks and uncertainties. Information regarding these risks and uncertainties is included in our public documents filed with the Securities and Exchange Commission. For a discussion of some of the risks and important factors that could affect Mindray's actual results and financial condition, see "Risk Factors" in Part I, Item 3D of Mindray's Annual Report on Form 20-F for the fiscal year ended December 31, 2008 and "Operating and Financial Review and Prospects" in Part I, Item 5 of Mindray's Annual Report on Form 20-F for the fiscal year ended December 31, 2008. Mindray does not undertake any obligation to update any forward-looking statement, except as required under applicable law. All information provided in this press release is as of June 30, 2009, and Mindray undertakes no duty to update such information, except as required under applicable law.
For investor and media inquiries please contact:
In the U.S.:
Evan Smith, CFA
FD
Tel: +1-212-850-5606
Email: evan.smith@fd.com
John Capodanno
FD
Tel: +1-212-850-5705
Email: john.capodanno@fd.com
In China:
Cathy Gao
Mindray Medical International Limited
Tel: +86-755-2658-2518
Email: cathy.gao@mindray.com
